Press

Newsroom

Featured articles

ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market

GlobeNewswire
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

ImpriMed Launches Advanced Precision Medicine Service for Canine Blood Cancers

PR Underground
Learn More →

Which Drugs Can Kill Your Dog's Cancer Cells? - ImpriMed's Sungwon Lim | Canine Cancer Rebel

Canine Cancer Alliance
Learn More →

ImpriMed: A data-driven, personalized chemotherapy drug testing service for canine blood cancer patients

Veterinary Cancer Society Annual Conference 2021
Learn More →

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

Veterinary Cancer Society Annual Conference 2020
Learn More →

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

Veterinary and Comparative Oncology
Learn More →

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

World Veterinary Cancer Congress 2020
Learn More →

From dog to human: precision medicine for comparative oncology

Precision Medicine World Conference 2020
Learn More →

Interview with Sungwon Lim: Founder & CEO of ImpriMed

Entrepreneurship, Interviews, Level Up!
Learn More →

ImpriMed: precision medicine for pet cancer care

NYC Oncology Conference 2019
Learn More →

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

Veterinary Cancer Society Annual Conference 2019
Learn More →

ImpriMed Raises $4M for Customized Cancer Treatments for Dogs

GlobeNewswire
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →